SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Bristol Myers Squibb's CAMZYOS Approved for Expanded Indication by FDA

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The approval covers both adult and pediatric patients weighing 30 kg and above, aiming to improve functional capacity and symptoms.

BMY

Related stories